SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Trimethoprim and sulfamethoxazole Tablets

Trade Name: SEPTRA, PARKAZOLE

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4
Reproductive Toxicity: Category 2

EU Classification:

EU Indication of danger: Toxic to Reproduction: Category 3
Harmful

EU Risk Phrases:
R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.

Label Elements

Signal Word: Warning
Hazard Statements:
H302 - Harmful if swallowed
H361d - Suspected of damaging the unborn child
Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P281 - Use personal protective equipment as required
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P330 - Rinse mouth
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards
No data available

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimethoprim</td>
<td>738-70-5</td>
<td>212-006-2</td>
<td>T;R25</td>
<td>Repr. Cat. 3; R63</td>
<td>15</td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>723-46-6</td>
<td>211-963-3</td>
<td>Repr. Cat. 3; R63</td>
<td>Repro. 2; H361d</td>
<td>74</td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1</td>
<td>208-534-8</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>9063-38-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>FD &amp; C Red No. 40</td>
<td>25956-17-6</td>
<td>247-368-0</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Docusate Sodium</td>
<td>577-11-7</td>
<td>209-406-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Material Name: Trimethoprim and sulfamethoxazole Tablets

Revision date: 20-Nov-2014

Version: 2.0

Page 3 of 10

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits fumes of carbon dioxide sulfur oxides nitrogen oxides

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Trimethoprim
Pfizer OEL TWA-8 Hr: 100µg/m³

Starch, pregelatinized
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Czech Republic OEL - TWA 4.0 mg/m³
Greece OEL - TWA 10 mg/m³
5 mg/m³
Ireland OEL - TWAs 10 mg/m³
4 mg/m³
OSHA - Final PELS - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
Slovakia OEL - TWA 4 mg/m³
Spain OEL - TWA 10 mg/m³
Switzerland OEL - TWAs 3 mg/m³

Sulfamethoxazole
Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000µg/m³ to 3000µg/m³)

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Tablet</th>
<th>Color:</th>
<th>Pink</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available.</td>
<td>Odor Threshold:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium Stearate</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Docusate Sodium</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FD &amp; C Red No. 40</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decomposition Temperature (°C):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor Pressure (kPa):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor Density (g/ml):</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relative Density:</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viscosity:</td>
<td>No data available.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Flammability:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoignition Temperature (Solid) (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (Solids):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
</tr>
</tbody>
</table>
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: None known
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May be harmful if swallowed. (based on animal data).
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.
Known Clinical Effects: Adverse effects associated with therapeutic use include nausea, diarrhea, blood cell changes, muscle pain, skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis), kidney toxicity (nephrotoxicity). Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium benzoate
- Rat Oral LD50 4,070 mg/kg
- Mouse Oral LD50 1600mg/kg

Trimethoprim
- Rat Oral LD50 200 mg/kg
- Rat Sub-tenon injection (eye) LD50 500mg/kg
- Mouse Oral LD50 2764mg/kg
- Mouse Intravenous LD50 200mg/kg
- Mouse Intraperitoneal LD50 1870mg/kg

Sulfamethoxazole
- Rat Oral LD 50 6370
- Mouse Oral LD 50 2650
- Rat Intraperitoneal LD 50 2690
- Mouse Intraperitoneal LD 50 2300

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate
- 13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Sodium benzoate
- 10 Day(s) Rat Oral 27370 mg/kg LOAEL Liver, Blood
- 10 Day(s) Mouse Oral 45 g/kg LOAEL Liver, Kidney, Blood, Ureter, Bladder
11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sodium benzoate
Embryo / Fetal Development  Rat  Oral  44 g/kg  LOEL  Developmental toxicity

Trimethoprim
Reproductive & Fertility-Males  Rat  Oral  70 mg/kg/day  NOAEL  Fertility
Reproductive & Fertility - Females  Rat  Oral  14 mg/kg/day  NOAEL  Fertility
Embryo / Fetal Development  Rabbit  Oral  30 mg/kg  LOAEL  Embryotoxicity
Embryo / Fetal Development  Rat  Oral  200 mg/kg  LOAEL  Maternal Toxicity, Teratogenic
Embryo / Fetal Development  Mouse  Oral  70 mg/kg  NOAEL  Not Teratogenic

Sulfamethoxazole
Embryo / Fetal Development  Rat  Oral  512 mg/kg/day  NOEL  Teratogenic
Reproductive & Fertility  Rat  Oral  350 mg/kg/day  NOAEL  No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Trimethoprim
Bacterial Mutagenicity (Ames)  Salmonella, E. coli  Negative
In Vitro Chromosome Aberration  Chinese Hamster Ovary (CHO) cells  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Negative

Sulfamethoxazole
Bacterial Mutagenicity (Ames)  Salmonella  Negative
In Vivo Chromosome Aberration  Human Lymphocytes  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Sulfamethoxazole
60 Week(s)  Rat  Oral  60  LOEL  Tumors, Thyroid

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Sulfamethoxazole
IARC:  Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:  Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Trimethoprim  Daphnia magna (Water Flea)  OECD  LC50  48 Hours  141 mg/L
SAFETY DATA SHEET

Material Name: Trimethoprim and sulfamethoxazole Tablets

Revision date: 20-Nov-2014

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 1, Subdivision B
Class D, Division 2, Subdivision A

Trimethoprim
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List 212-006-2

PZ02041
15. REGULATORY INFORMATION

Sulfamethoxazole

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List: 211-963-3

Starch, pregelatinized

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 232-679-6

Sodium benzoate

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 208-534-8

Sodium starch glycolate

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: Not Listed

FD & C Red No. 40

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 247-368-0

Docusate Sodium

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-406-4

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3
Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

T - Toxic
Toxic to Reproduction: Category 3

R25 - Toxic if swallowed.
R63 - Possible risk of harm to the unborn child.

Data Sources:
Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision:
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 20-Nov-2014
Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet